Free. Unsubscribe any time.
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. filed 42 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 5 reporting owners, covering 96 transactions and 779,870 shares. 42 carry the SEC's AFF10B5ONE flag; 0 name a plan only in a footnote. 4 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2025-10-14, came 5 days after the one before it (2025-10-09) and reports 3 transactions against 4 in the filing before it.
- The sales it reports total 30,000 shares, 17,500 more than the 12,500 in the filing before it.
- Its 42 plan statements rank 132nd of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 42 filings on file run from 2025-01-06 to 2025-10-14, and state no plan adoption date.
Trades in Akero Therapeutics, Inc. 96
- Young Jonathan — 2025-01-02 · S · 10,000 shares
- Cheng Andrew — 2025-01-27 · S · 24,242 shares
- Cheng Andrew — 2025-01-27 · S · 2,381 shares
- Cheng Andrew — 2025-01-27 · S · 3,377 shares
- Lamy Patrick — 2025-01-27 · S · 5,000 shares
- Rolph Timothy — 2025-01-27 · S · 13,812 shares
- Rolph Timothy — 2025-01-27 · S · 5,059 shares
- Rolph Timothy — 2025-01-27 · S · 12,379 shares
- Yale Catriona — 2025-01-27 · S · 25,907 shares
- Yale Catriona — 2025-01-27 · S · 14,467 shares
- Yale Catriona — 2025-01-27 · S · 8,700 shares
- Yale Catriona — 2025-01-27 · S · 17,000 shares
Adoption dates in Akero Therapeutics, Inc. 0
Results prints in Akero Therapeutics, Inc. 4
- 2025-01-27
- 2025-02-28
- 2025-05-12
- 2025-08-08
Trades before a print in Akero Therapeutics, Inc. 19
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Cheng Andrew · 24,242 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Cheng Andrew · 2,381 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Cheng Andrew · 3,377 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Lamy Patrick · 5,000 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Rolph Timothy · 13,812 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Rolph Timothy · 5,059 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Rolph Timothy · 12,379 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Yale Catriona · 25,907 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Yale Catriona · 14,467 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Yale Catriona · 8,700 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Yale Catriona · 17,000 shares
- 0 days before the 2025-01-27 print — 2025-01-27 · S · Yale Catriona · 9,250 shares
Interval to Akero Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 19within 5 days
- 24within 10 days
- 0shortest, days
- 19no later print
- Cheng Andrew 2025-01-27 · S · 0 days before the 2025-01-27 print · President and CEO
- Cheng Andrew 2025-01-27 · S · 0 days before the 2025-01-27 print · President and CEO
- Cheng Andrew 2025-01-27 · S · 0 days before the 2025-01-27 print · President and CEO
- Lamy Patrick 2025-01-27 · S · 0 days before the 2025-01-27 print · Senior VP, Commercial Strategy
- Rolph Timothy 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Scientific Officer
- Rolph Timothy 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Scientific Officer
- Rolph Timothy 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Scientific Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-01-27 · S · 0 days before the 2025-01-27 print · Chief Development Officer
- Yale Catriona 2025-02-18 · S · 10 days before the 2025-02-28 print · Chief Development Officer
- Yale Catriona 2025-02-18 · S · 10 days before the 2025-02-28 print · Chief Development Officer
- Rolph Timothy 2025-05-06 · S · 6 days before the 2025-05-12 print · Chief Scientific Officer
- Rolph Timothy 2025-05-06 · S · 6 days before the 2025-05-12 print · Chief Scientific Officer
- Rolph Timothy 2025-05-06 · S · 6 days before the 2025-05-12 print · Chief Scientific Officer
- Lamy Patrick 2025-05-07 · S · 5 days before the 2025-05-12 print · Senior VP, Commercial Strategy
- Lamy Patrick 2025-05-07 · S · 5 days before the 2025-05-12 print · Senior VP, Commercial Strategy
Reported results dates on file
- 2025-01-27
- 2025-02-28
- 2025-05-12
- 2025-08-08
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.